


	2019	2023	2024	2025	Δ 2025-2019	GRI Indicator
Climate Change – Public Targets¹						
Scope 1 + 2 (metric ton (mt) CO ₂ e) ^{2,3,4}	1,265,496	1,102,416	1,130,367	748,506	↓ 41%	305-1 305-2
Renewable Energy (%) ²	9.5%	9.9%	14.1%	68.7%	↑ 59%	-
Scope 3 – Business travel (mt CO ₂ e) ^{5,11}	421,399	186,396	188,309	175,200	↓ 58%	305-3
Scope 3 – Upstream transportation & distribution (mt CO ₂ e) ^{5,9}	200,873	257,319	154,001	110,146	↓ 45%	305-3
Scope 3 – Suppliers of purchased goods and services by spend with science-based targets (%) ⁶	-	51%	65%	72%	-	305-3


Pfizer is committed to achieving the voluntary Net-Zero standard by 2040. Our near-term climate goals, approved by the Science Based Targets initiative, are to:

- Reduce Scope 1+2 greenhouse gas (GHG) emissions **46%** by 2030 from a 2019 baseline.
- Source **80%** of electricity from renewables by 2025 and **100%** by 2030.
- Reduce GHG emissions from business travel **25%** by 2025 from a 2019 baseline.
- Reduce GHG emissions from upstream transportation and distribution **10%** by 2025 from a 2019 baseline.
- Catalyze **64%** of our suppliers of goods and services by spend to set science-based targets by 2025.

	2019	2023	2024	2025	Δ 2025-2019	Δ 2025-2024	GRI Indicator
Climate Change – Additional Metrics¹							
Scope 1 (mt CO ₂ e) ^{2,3}	695,107	615,589	616,829	614,274	↓ 12%	↓ 0.4%	305-1
Scope 2, market-based (mt CO ₂ e) ^{2,4}	570,388	486,827	513,538	134,232	↓ 77%	↓ 74%	305-2
Scope 2, location-based (mt CO ₂ e) ^{2,4}	558,111	449,647	440,499	422,876	↓ 24%	↓ 4%	305-2
Scope 1 + 2 Emissions Intensity (mt CO ₂ e/million USD revenue) ^{2,3,4}	31.0	18.6	16.9	12.0	↓ 61%	↓ 29%	305-4
Energy Consumed (MWh) ²	4,787,389	4,466,375	4,437,907	1,445,718	↓ 70%	↓ 67%	302-1
Energy Intensity (MWh/million USD revenue) ²	117.0	75.0	69.8	23.1	↓ 80%	↓ 67%	302-3
Scope 3 – Purchased goods and services (mt CO ₂ e) ^{5,7}	1,900,504	3,401,334	2,786,489	2,647,407	↑ 39%	↓ 5%	305-3
Scope 3 – Capital goods (mt CO ₂ e) ^{5,7}	101,679	126,588	119,357	164,066	↑ 61%	↑ 37%	305-3
Scope 3 – Fuel-and-energy-related activities not in Scope 1 or 2 (mt CO ₂ e) ^{5,8}	252,909	263,780	254,803	231,527	↓ 8%	↓ 9%	305-3
Scope 3 – Waste generated in operations (mt CO ₂ e) ^{5,10}	9,512	8,795	5,435	4,433	↓ 53%	↓ 18%	305-3
Scope 3 – Employee commuting (mt CO ₂ e) ^{5,12}	60,645	21,745	20,564	18,953	↓ 69%	↓ 8%	305-3
Scope 3 – Upstream leased assets (mt CO ₂ e) ^{5,13}	36,273	26,497	15,511	12,982	↓ 64%	↓ 16%	305-3
Scope 3 – Downstream transportation and distribution (mt CO ₂ e) ¹⁴	99,576	4,446	3,397	37,626	↓ 62%	↑ 1008%	305-3
Scope 3 – Investments (mt CO ₂ e) ^{5,15}	33,892	6,754	7,342	6,605	↓ 81%	↓ 10%	305-3
Scope 3 – Total (mt CO ₂ e)	3,117,262	4,303,654	3,555,207	3,408,946	↑ 14%	↓ 17%	305-3



	2023	2024	2025	Δ 2025-2024	GRI Indicator
Water ^{1,16,17}					
Water withdrawal excluding non-contact cooling water (million m ³)	12.3	12.1	11.7	↓ 4%	303-3
Water withdrawal including non-contact cooling water (million m ³)	31.8	30.9	26.6	↓ 14%	303-3
Third-party water (million m ³)	7.5	7.3	7.2	↓ 5%	303-3
Surface water withdrawal (million m ³)	0.77	0.73	0.65	↓ 10%	303-3
Groundwater withdrawal (million m ³)	23.4	22.7	18.8	↓ 17%	303-3
Brackish/seawater withdrawal (million m ³)	0	0	0	-	303-3
Water discharged (million m ³)	29.0	27.7	23.9	↓ 14%	303-4
Water consumed (million m ³)	2.8	3.2	2.8	↓ 14%	303-5
Waste ^{1,18,19}					
Hazardous waste generated (thousand metric tons)	80.3	79.6	77.8	↓ 2%	306-3
Hazardous waste diverted from disposal (thousand metric tons)	10.4	12.6	4.9	↓ 61%	306-4
Hazardous waste incinerated with energy recovery (thousand metric tons)	51.3	51.6	59.7	↑ 16%	306-5
Hazardous waste incinerated without energy recovery (thousand metric tons)	13.8	10.1	10.0	↓ 1%	306-5
Hazardous waste landfilled (thousand metric tons)	0.02	0.04	0.04	↓ 17%	306-5
Hazardous waste other treatment (thousand metric tons)	4.8	5.2	3.1	↓ 41%	306-5
Hazardous waste disposed (thousand metric tons)	69.9	67.0	72.9	↑ 9%	306-5
Hazardous waste diverted from disposal (%)	13%	16%	6%	-	306-4
Non-hazardous waste generated (thousand metric tons)	36.2	34.5	32.9	↓ 5%	306-3
Non-hazardous waste diverted from disposal (thousand metric tons)	19.2	19.6	18.9	↓ 3%	306-4
Non-hazardous waste incinerated with energy recovery (thousand metric tons)	5.5	7.4	8.0	↑ 8%	306-5
Non-hazardous waste incinerated without energy recovery (thousand metric tons)	1.2	0.6	0.5	↓ 28%	306-5
Non-hazardous waste landfilled (thousand metric tons)	10.1	6.7	5.2	↓ 22%	306-5
Non-hazardous waste other treatment (thousand metric tons)	0.2	0.2	0.3	↑ 38%	306-5
Non-hazardous waste disposed (thousand metric tons)	17.0	14.9	14.0	↓ 6%	306-5
Non-hazardous waste diverted from disposal (%)	53%	57%	57%	-	306-4




	2023	2024	2025	Δ 2025-2024	GRI Indicator
Air Emissions ¹					
Volatile organics (thousand kg)	512.4	283.6	307.3	↑ 8%	305-7
Health & Safety					
Fatalities ²¹	0	2	0	-	403-9 403-10
Recordable injuries & illnesses	258	256	237	↓ 7%	403-9 403-10
Lost time injuries & illnesses	114	123	117	↓ 5%	403-9 403-10
Hours worked (millions)	172.9	165.1	167.5	↑ 1%	403-9 403-10
Total Injury & Illness Rate (Recordable cases per 200,000 hours worked) ²⁰	0.30	0.31	0.28	↓ 10%	403-9 403-10
Total Lost Time Injury & Illness Rate (Lost time cases per 200,000 hours worked) ²⁰	0.13	0.15	0.14	↓ 7%	403-9 403-10
Fleet Safety (Collisions per million km driven)	7.93	7.54	8.05	↑ 7%	-
Compliance					
Number of EHS penalties paid ²²	1	4	0	-	307-1
EHS Penalties paid (currency equivalent USD) ²²	111,600	18,600	0	-	307-1
Supplier EHS assessments (number performed)	109	90	77	-	308-2

NOTES

↓=decrease (reduction) ↑=increase

Notes

^{1.} Pfizer's organizational boundaries for environmental performance include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted, reported absolute, using reporting boundaries defined per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol.



NOTES


Climate Change

Scope 1 & 2

2. Data presented represents information available as of April 8, 2026, including certain estimates and assumptions. Historical estimates may periodically be subject to revision due to data source restatements and updates to methodology. Baseline year data (2019) has been independently verified to the limited assurance level; 2021-2025 data is independently assured to the reasonable assurance level. See Pfizer's [website](#) for our GHG calculation methodology and assurance reports.
3. Scope 1 emissions include CO₂, CH₄, N₂O, SF₆, and refrigerants using IPCC Fifth Assessment Report (AR5-100 year) Global Warming Potential (GWP) rates; volatile organic emissions are calculated using an emission factor representative of solvents typically used by Pfizer sites.
4. Scope 2 emissions are reported in accordance with GHG Protocol Scope 2 Guidance as location- and market-based emissions. Location-based emissions are calculated based on the average emissions intensity of the grid for the region where energy is consumed. Market-based emissions are calculated based on the electricity procured by individual locations, with emission factors derived from contractual instruments.

Scope 3

5. Data presented represents information available as of May 26, 2026, including certain estimates and assumptions. Historical estimates may periodically be subject to revision due to data source restatements and updates to methodology. 2019 and 2024 data is independently assured to the limited assurance level, and assurance of 2025 data is underway. Seagen's Scope 3 emissions are included in Pfizer's data beginning in 2024. Seagen's 2019 Scope 3 emissions were considered non-material (less than 5% of total emissions in each category) and were not included in our baseline. See Pfizer's [website](#) for our GHG calculation methodology and assurance reports.
6. Supplier engagement – Tracking of the Scope 3 supplier engagement goal was initiated in 2021. We include companies that have publicly committed to setting science-based targets through the Science Based Target Initiative (SBTi), companies with SBTi-validated targets, and companies with Scope 1 and 2 targets set at a level equivalent to SBTi criteria.
7. Purchased goods and services & capital goods – 2019, 2023 and 2024 emissions calculated based on spend using US EPA Supply Chain Greenhouse Gas Emission Factors (v1.2 by NAICS-6), adjusted for inflation. To better capture emissions at the supplier level, 2025 emissions are calculated using an updated hybrid methodology that applies supplier-specific emission factors where available, or industry-average emission factors based on each supplier's sector, covering suppliers representing over 90% of total spend. Supplier-specific emission factors are derived from latest publicly reported emissions and financial data, identified and compiled using artificial intelligence tools. The remaining spend (less than 10%) is aggregated by material categories and groups and mapped to industry-average emission factors.
8. Fuel-and-energy-related activities – 2025 fuel-related emissions calculated using 2025 UK Government GHG Conversion Factors for Company Reporting. Emissions associated with production and transmission and distributions of electricity, heat and steam calculated using 2025 UK Government GHG Conversion Factors and 2025 IEA Emission Factors.
9. Upstream transportation & distribution – Upstream transportation emissions are calculated from Pfizer and third-party datasets. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers are excluded here as they are included in Category 1, Purchased Goods and Services. Due to limited data availability, emissions associated with market logistics and the operation of third-party logistics centers outside of the US are not included in reporting. In 2025 we continued applying low emissions fuels certificates provided by logistics suppliers, covering approximately 61,000 metric tons of emissions. Including the impact of these certificates, emissions were 45% below the 2019 baseline; excluding their impact, emissions were 15% below the baseline.
10. Waste generated in operations – 2025 emissions calculated using UK Government GHG Conversion Factors for Company Reporting (2025).
11. Business travel – Emissions calculated by Pfizer's travel partner, using a proprietary methodology certified under ISO 14064-1:2018 & 2019, and by Pfizer's US fleet reimbursement management provider. Air travel emissions for all years, including the 2019 baseline, have been adjusted to include well-to-wheel (WTW) emissions in accordance with the GHG Protocol. There may be differences in baseline and subsequent reporting year values due to changes in the business that require baseline adjustments conducted in accordance with the GHG Protocol. Air travel emissions



NOTES

for all years, including the 2019 baseline, have been adjusted to include well-to-wheel (WTW) emissions. Estimates for travel booked outside Pfizer's travel system, which account for less than 10% of total business travel emissions, are included for all years.

12. Employee commuting – Emissions estimated using US EPA Climate Leaders GHG and DEFRA emission factors. Remote workers are excluded from the emissions estimate.
13. Upstream leased assets – Emissions for 2023, 2024, and 2025 were calculated from actual energy consumption where available following the same methodology used for calculating Scope 1 & 2 emissions (see notes 3 & 4 above). Emissions from other leased locations were calculated based on floor space using average emission factors. From 2024 onwards we updated our estimation methodology to reflect location type (e.g., laboratory, office, storage).
14. Downstream transportation and distribution – Emissions for 2025 reflect a significant update to the calculation methodology, incorporating improved activity data and emission factors to better represent downstream logistics emissions. In addition, the scope of reporting has been expanded to include downstream transportation of final products across all regions globally, whereas prior years were limited primarily to the United States and Europe. As a result of these methodological changes and expanded coverage, 2025 emissions are not directly comparable to prior years, and the increase observed compared to 2024 is primarily attributable to the updated methodology rather than underlying changes in operational activity. Assurance of the 2025 data is underway.
15. Investments – Emissions data provided by Pfizer's joint venture operations where we have influence and/or operational control.

Water

16. Pfizer strives to reduce freshwater use from its internal operations. Our [Water Stewardship position statement](#) describes our efforts to be good stewards of water with a particular focus on water stressed areas.
17. Data is independently assured at the limited assurance level. See Pfizer's [website](#) for our calculation methodology and assurance reports.

Waste

18. Pfizer strives to reduce waste from its operation through applying a hierarchy of control of handling waste: avoid, reduce, reuse, recycle, disposal. Each site has established targets to improve the circularity of their waste, we continue to enhance our waste management practices, and we benchmark our performance against others in our industry. The reported decrease in recycling was largely due to the reclassification of a waste stream previously reported as recycled upon confirmation that it was managed through incineration with energy recovery, which Pfizer does not classify as recycled or diverted from disposal. Prior year figures were not restated to reflect this change in classification as it was insignificant to total waste generation.
19. 2023 through 2025 hazardous waste data and 2025 non-hazardous waste data are independently assured at the limited assurance level. See Pfizer's [website](#) for our calculation methodology and assurance reports.

Health & Safety

20. Pfizer's global total injury & illness rate and total lost time injury rate is based on the U.S. Occupational Safety and Health Administration (OSHA) recording criteria.
21. Work-related injuries or illnesses that led to loss of life. Both reported cases in 2024 were related to motor vehicle collisions.

Compliance

22. Compliance with applicable environmental, health and safety (EHS) laws in the jurisdictions where we operate, complemented by our internal EHS Standards, is the foundation of our EHS program. Pfizer is dedicated to maintaining full EHS compliance, and when potential non-compliance is identified, including when identified through self-assessment and compliance assurance programs, prompt corrective action is required. Our internal EHS Standards and routine internal EHS audits assist in maintaining compliance and providing a strong driver for continuous improvement.